Press Releases

Date Title  
06/05/19 Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA
– Preparations Continue for Submission of BLA in the U.S. and MAA in Europe – SEATTLE --(BUSINESS WIRE)--Jun. 5, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that the European Medicines Agency (EMA) has appointed rapporteurs for the company’s marketing authorization application (MAA)
05/15/19 Omeros to Present at the UBS Global Healthcare Conference
SEATTLE --(BUSINESS WIRE)--May 15, 2019-- Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the UBS Global Healthcare Conference in New York next week. The presentation is scheduled for Wednesday, May 22, 2019 at
05/09/19 Omeros Corporation Reports First Quarter 2019 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 9, 2019-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
05/07/19 Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting
- Cataract surgery performed using OMIDRIA had lower rates of CME than cataract surgery using postoperative steroids- SEATTLE --(BUSINESS WIRE)--May 7, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced the results of a real-world clinical study showing that its FDA -approved ophthalmic drug
05/06/19 Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019
SEATTLE --(BUSINESS WIRE)--May 6, 2019-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter 2019 financial results for the period ended March 31, 2019 , on Thursday, May 9, 2019 , after the market closes. Omeros management will host a conference call
05/01/19 Omeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting
SEATTLE --(BUSINESS WIRE)--May 1, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced that the results of an investigator-sponsored real-world study of its FDA -approved ophthalmic drug OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% will be presented at the American
04/03/19 Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment
-- Growing Identification of HSCT-TMA a Focus of Recent Annual Meeting of the European Society for Blood and Marrow Transplantation -- SEATTLE --(BUSINESS WIRE)--Apr. 3, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced the recent presentation of a case report describing resolution of
03/19/19 Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation
--Session Will Focus on Diagnosis of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy-- SEATTLE --(BUSINESS WIRE)--Mar. 19, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced an upcoming educational event at the 2019 Annual Meeting of the European Society of Blood and
03/01/19 Omeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results
– Conference Call Today at 8:30 a.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 1, 2019-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
02/26/19 Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019
SEATTLE --(BUSINESS WIRE)--Feb. 26, 2019-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end 2018 financial results for the period ended December 31, 2018 , on Friday, March 1, 2019 , before the market opens.
02/20/19 Omeros Corporation Announces USAN and INN Selection of Nonproprietary Name for OMS721
SEATTLE --(BUSINESS WIRE)--Feb. 20, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that, as the company prepares for planned commercialization of OMS721, the United States Adopted Names (USAN) Council , in consultation with the World Health Organization’s International Nonproprietary
02/14/19 Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA
Patient Data from Existing Single-Arm Study Will Form the Basis for BLA; No Historical Control Required SEATTLE --(BUSINESS WIRE)--Feb. 14, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that, based on a recent meeting with the U.S. Food and Drug Administration ( FDA ), the company has
02/12/19 Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors
-- Former Lilly Biotechnology and Immunology Senior Vice President Drawn by Omeros’ Complement Franchise and Novel-Product Pipeline -- SEATTLE --(BUSINESS WIRE)--Feb. 12, 2019-- Omeros Corporation (NASDAQ: OMER) today announced the appointment of Thomas F. Bumol , Ph.D., to its Board of Directors.
01/17/19 Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy
--Additional Positive Data Reported from Second Cohort in Phase 2 Trial-- SEATTLE --(BUSINESS WIRE)--Jan. 17, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that it has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy (IgAN) following a recent
01/14/19 Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018
– Broadening OMIDRIA Coverage from Payers and Increasing Funding for OMS721 Commercial Preparations – SEATTLE --(BUSINESS WIRE)--Jan. 14, 2019-- Omeros Corporation (Nasdaq: OMER), today announced unaudited preliminary revenue results for the fourth quarter ended December 31, 2018 .
12/20/18 Omeros Establishes Independent Academic Leadership Committee for its OMS721 Phase 3 Clinical Program in IgA Nephropathy
-- Committee is Comprised of World Leaders in IgA Nephropathy and Renal Clinical Research -- SEATTLE --(BUSINESS WIRE)--Dec. 20, 2018-- Omeros Corporation (Nasdaq: OMER) announced today the formation of an independent Academic Leadership Committee (ALC) to support its Phase 3 clinical program for
12/11/18 Omeros Announces Research Collaboration with University of Cambridge
Newly Established Center Will Focus on Complement and Inflammation SEATTLE --(BUSINESS WIRE)--Dec. 11, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a research collaboration with the University of Cambridge , establishing the Omeros Center at Cambridge for
12/06/18 Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)
– EMA Confirmed OMS721 Eligibility for European Centralized Marketing Authorization Application Review – SEATTLE --(BUSINESS WIRE)--Dec. 6, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that it has submitted a pediatric investigational plan (PIP) for the use of OMS721 for the treatment
12/03/18 Omeros Announces Additions to Senior Management Team
-- Hires Commercial and CMC Heads from Celgene -- SEATTLE --(BUSINESS WIRE)--Dec. 3, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that it hired two new senior management team members – Daniel Kirby as vice president and head of commercial and Justin McCue , Ph.D.
11/09/18 Omeros Announces Pricing of $210 Million Offering of Convertible Senior Notes Due 2023
-- Initial Purchasers Have Option to Purchase $40 Million of Additional Notes -- SEATTLE --(BUSINESS WIRE)--Nov. 9, 2018-- Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced the pricing of an offering of $210 million aggregate principal amount of its 6.25% Convertible Senior Notes due
11/08/18 Omeros Announces Proposed $210 Million Offering of Convertible Senior Notes Due 2023
SEATTLE , Nov. 8, 2018 /PRNewswire/ --  Omeros Corporation (Nasdaq: OMER) (" Omeros ") today announced its intention to offer, subject to market and other conditions, $210 million aggregate principal amount of its Convertible Senior Notes due 2023 (the "Notes") in a private offering (the
11/08/18 Omeros Corporation Reports Third Quarter 2018 Financial Results
– Conference Call Friday, November 9th at 8:30 a.m. ET – SEATTLE --(BUSINESS WIRE)--Nov. 8, 2018-- Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2018 , which include: 3Q 2018 total and
11/05/18 Omeros Corporation to Announce Third Quarter 2018 Financial Results on November 9, 2018
SEATTLE --(BUSINESS WIRE)--Nov. 5, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter 2018 financial results for the period ended September 30, 2018 , on Friday, November 9, 2018 , before the market opens.
10/23/18 FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
-- OMS721 now with orphan designation covering both prevention and treatment of HSCT-TMA in U.S. and in Europe -- SEATTLE --(BUSINESS WIRE)--Oct. 23, 2018-- Omeros Corporation (NASDAQ:OMER) today announced that OMS721 has received orphan drug designation from the U.S.
10/01/18 Omeros Corporation Announces Additional Positive Data for OMS721 in IgA Nephropathy
-- Magnitude of Proteinuria Reduction Consistent With Previous Cohort -- SEATTLE --(BUSINESS WIRE)--Oct. 1, 2018-- Omeros Corporation  (NASDAQ: OMER) today announced positive data from the company’s ongoing Phase 2 clinical trial of OMS721 for the treatment of renal diseases.
10/01/18 Omeros Corporation Announces Reinstatement of Pass-Through Status for OMIDRIA®
-- CMS’ Separate Payment for Cataract Surgery Drug Resumes Today -- SEATTLE --(BUSINESS WIRE)--Oct. 1, 2018-- Omeros Corporation  (NASDAQ: OMER) announced that reinstatement of separate payment by the Centers for Medicare and Medicaid Services (CMS) under the pass-through program for the company’s
09/27/18 Omeros to Present at the 2018 Cantor Global Healthcare Conference
SEATTLE --(BUSINESS WIRE)--Sep. 27, 2018-- Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2018 Cantor Global Healthcare Conference in New York next week. The presentation is scheduled for Tuesday, October
09/07/18 Omeros to Present at the Morgan Stanley Global Healthcare Conference
SEATTLE --(BUSINESS WIRE)--Sep. 7, 2018-- Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 16 th Annual Morgan Stanley Global Healthcare Conference in New York next week.
08/28/18 European Commission Designates OMS721 as an Orphan Medicinal Product for Treatment in Hematopoietic Stem Cell Transplantation
SEATTLE --(BUSINESS WIRE)--Aug. 28, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that the European Commission (EC) has adopted a decision designating OMS721 as an Orphan Medicinal Product in the European Union (EU) for treatment in hematopoietic stem cell transplantation (HSCT).
08/10/18 Omeros to Present at the 2018 Wedbush PacGrow Healthcare Conference
SEATTLE --(BUSINESS WIRE)--Aug. 10, 2018-- Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2018 Wedbush PacGrow Healthcare Conference in New York next week. The presentation is scheduled for Tuesday,
08/09/18 Omeros Corporation Reports Second Quarter 2018 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Aug. 9, 2018-- Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2018 , which include: 2Q 2018 total and OMIDRIA ® revenues were
08/03/18 Omeros Corporation to Announce Second Quarter 2018 Financial Results on August 9, 2018
SEATTLE --(BUSINESS WIRE)--Aug. 3, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its second quarter 2018 financial results for the period ended June 30, 2018 , on Thursday, August 9, 2018 , after the market closes.
08/02/18 Omeros Hires Former Sanofi Global Development Head as Chief Medical Officer
– Company Expands Leadership to Keep Pace with Advancing Pivotal Clinical Programs – SEATTLE --(BUSINESS WIRE)--Aug. 2, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that Eckhard Leifke, M.D. has been named Omeros’ Chief Medical Officer and Vice President of Clinical Development.
07/26/18 Sandoz Amends ANDA to Not Seek Approval for Generic Version of OMIDRIA Until Patents for Omeros’ Drug Expire
-- With Voluntary Dismissal of Infringement Suit Against Sandoz, Omeros Wraps Up All Pending ANDA Litigation -- SEATTLE --(BUSINESS WIRE)--Jul. 26, 2018-- Omeros Corporation  (Nasdaq: OMER) today announced that its patent infringement lawsuit against Sandoz Inc.
07/25/18 Omeros’ OMS721 Receives European Orphan Drug Designation Positive Opinion for Treatment in Hematopoietic Stem Cell Transplantation
-- Discussions Ongoing with European Regulators for Pathway to Expedited Approval -- SEATTLE --(BUSINESS WIRE)--Jul. 25, 2018-- Omeros Corporation (Nasdaq: OMER) announced today that the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) issued a positive opinion
07/23/18 Omeros Corporation Initiates Sales of OMIDRIA® in Europe
-- Sales maintain the drug’s European marketing authorization -- SEATTLE --(BUSINESS WIRE)--Jul. 23, 2018-- Omeros Corporation (NASDAQ: OMER) today announced initial sales of OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1%/0.3% in Europe .
07/17/18 Omeros Initiates Dosing in Phase 1 Clinical Trial for OMS527 Targeting Addiction
-- Nicotine Addiction Planned as First Indication -- SEATTLE --(BUSINESS WIRE)--Jul. 17, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the first cohort of subjects has been dosed in the Company’s Phase 1 clinical trial, evaluating the lead phosphodiesterase 7 (PDE7) inhibitor in
06/27/18 Omeros Obtains Approval to Initiate Phase 1 Clinical Trial for its OMS527 Addiction Treatment
– First Clinical Target for PDE7 Inhibitor to be Nicotine Addiction – SEATTLE --(BUSINESS WIRE)--Jun. 27, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory authority and ethics committee clearance to start the Phase 1 clinical trial evaluating its lead
05/24/18 Omeros Announces Settlement of Infringement Suit Against ANDA Filer Lupin
--Lupin Confirms Validity of OMIDRIA Patents-- SEATTLE --(BUSINESS WIRE)--May 24, 2018-- Omeros Corporation  (Nasdaq: OMER) today announced that it has entered into a settlement agreement with Lupin Ltd. and its subsidiary Lupin Pharmaceuticals, Inc. (Lupin), resolving Omeros’ patent litigation
05/10/18 Omeros Corporation Reports First Quarter 2018 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 10, 2018-- Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2018 , which include: 1Q 2018 total and OMIDRIA ® revenues were
05/07/18 Omeros Corporation to Announce First Quarter 2018 Financial Results on May 10, 2018
SEATTLE --(BUSINESS WIRE)--May 7, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its first quarter 2018 financial results for the period ended March 31, 2018 , on Thursday, May 10, 2018 , after the market closes. Omeros management will host a conference call
04/26/18 FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
– Discussions Ongoing with FDA and European Regulators for Expedited Approval – SEATTLE --(BUSINESS WIRE)--Apr. 26, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration ( FDA ) has granted breakthrough therapy designation to OMS721 for the treatment of
04/19/18 Additional Clinical Studies Supporting the Benefits of OMIDRIA® Presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting
-- OMIDRIA demonstrates clear benefits across traditional and femtosecond laser-assisted cataract surgery and in IFIS cases-- SEATTLE --(BUSINESS WIRE)--Apr. 19, 2018-- Omeros Corporation  (NASDAQ: OMER) announced that the results of four real-world clinical studies evaluating the benefits of
04/13/18 Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery Meeting
SEATTLE --(BUSINESS WIRE)--Apr. 13, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the results of four studies directed to the benefits of OMIDRIA across a range of clinical situations in cataract surgery will be presented at the upcoming American Society of Cataract and Refractive
04/12/18 OMIDRIA® Added to Veterans Health Administration National Formulary
-- OMIDRIA now available across the VA system to benefit U.S. veterans -- SEATTLE --(BUSINESS WIRE)--Apr. 12, 2018-- Omeros Corporation  (Nasdaq: OMER) today announced that the Veterans Administration (VA) has added OMIDRIA ® (phenylephrine and ketorolac intraocular solution 1% / 0.3%) to the VA
04/11/18 Omeros Announces Amendment of Credit Facility
SEATTLE --(BUSINESS WIRE)--Apr. 11, 2018-- Omeros Corporation  (Nasdaq: OMER) today announced that it has entered into an amendment to its existing credit facility with certain affiliates of CRG LP , a healthcare-focused investment firm. With respect to the twelve-month period beginning on January
03/01/18 Omeros Corporation Reports Fourth Quarter and Year-End 2017 Financial Results
Conference Call Today at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--Mar. 1, 2018-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
02/26/18 Omeros Corporation to Announce Fourth Quarter and Year-End 2017 Financial Results on March 1, 2018
SEATTLE --(BUSINESS WIRE)--Feb. 26, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end 2017 financial results for the period ended December 31, 2017 , on Thursday, March 1, 2018 , after the market closes.
02/15/18 Omeros Reports Significant Improvement in Overall Survival Data in OMS721-Treated Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
-- Greater than 16-Fold Improvement in Survival Compared to Historical Control -- SEATTLE --(BUSINESS WIRE)--Feb. 15, 2018-- Omeros Corporation (NASDAQ: OMER) today announced new results from the company’s ongoing Phase 2 study of OMS721 evaluating patients with hematopoietic stem cell
01/22/18 European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros’ OMS721 in the Treatment of IgA Nephropathy
-- EMA also reviewing Priority Medicines application for the drug in IgAN -- SEATTLE --(BUSINESS WIRE)--Jan. 22, 2018-- Omeros Corporation (Nasdaq: OMER) announced today that the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on Omeros’
01/03/18 Omeros Corporation Reaches Agreement with FDA on OMS721 Phase 3 Trial Protocol for IgA Nephropathy
-- Also Initiates OMS721 Phase 3 Program in HCT-TMA -- SEATTLE --(BUSINESS WIRE)--Jan. 3, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that it has reached agreement with the US Food and Drug Administration ( FDA ) on Omeros’ protocol for its Phase 3 clinical trial evaluating OMS721 in
12/12/17 Omeros Corporation Announces FDA Approval of OMIDRIA® for Use in Pediatric Patients
-- FDA Also Grants Additional Market Exclusivity -- SEATTLE --(BUSINESS WIRE)--Dec. 12, 2017-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as
11/09/17 Omeros Corporation Reports Third Quarter 2017 Financial Results
Conference Call Today at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--Nov. 9, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
11/06/17 Extended Improvement in OMS721-Treated Patients with IgA Nephropathy Presented at American Society of Nephrology Annual Meeting
SEATTLE --(BUSINESS WIRE)--Nov. 6, 2017-- Omeros Corporation  (NASDAQ: OMER) today announced that extended follow-up data from patients with immunoglobulin A (IgA) nephropathy treated with OMS721 were presented on November 4, 2017 at the American Society of Nephrology (ASN) Meeting in New Orleans .
11/06/17 Omeros Corporation to Announce Third Quarter 2017 Financial Results on November 9, 2017
SEATTLE --(BUSINESS WIRE)--Nov. 6, 2017-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter 2017 financial results for the period ended September 30, 2017 , on Thursday, November 9, 2017 , after the market closes.
11/01/17 Omeros Announces Upcoming Presentation of Clinical OMS721 Data at the American Society of Nephrology Annual Meeting
SEATTLE --(BUSINESS WIRE)--Nov. 1, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that a subset of data will be presented from the company’s Phase 2 clinical trial of OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), for
10/26/17 Omeros Reports Additional and Consistently Positive Data for OMS721 in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
-- Preparing to Initiate Phase 3 Clinical Program -- SEATTLE , Oct. 26, 2017 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced further positive data from the company's ongoing Phase 2 study of OMS721 evaluating patients with hematopoietic stem cell transplant-associated thrombotic
10/20/17 Report of Successful OMS721 Treatment of Patient with Both Stem Cell Transplant-Associated Thrombotic Microangiopathy and Graft-versus-Host Disease Presented at EBMT Annual Meeting
-- Results May Expand Target for Omeros’ Planned Phase 3 Program in HCT-TMA -- SEATTLE --(BUSINESS WIRE)--Oct. 20, 2017-- Omeros Corporation  (NASDAQ: OMER) today announced the presentation of a case report of a patient having co-existing hematopoietic stem cell transplant-associated thrombotic
10/16/17 Omeros Announces Upcoming Presentation of Clinical OMS721 Data at European Society for Blood and Marrow Transplantation
SEATTLE --(BUSINESS WIRE)--Oct. 16, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that data will be presented from the company’s Phase 2 clinical trial of OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), for the
10/05/17 Omeros Announces Settlement of Infringement Suit Against ANDA Filer Par
--Par Confirms Validity of OMIDRIA Patents and Agrees Not to Market a Generic Version of OMIDRIA Until 2032-- SEATTLE --(BUSINESS WIRE)--Oct. 5, 2017-- Omeros Corporation  (NASDAQ: OMER) today announced that it entered into a settlement agreement with Par Pharmaceutical, Inc.
08/23/17 Omeros Responds to Statnews.com Story
SEATTLE --(BUSINESS WIRE)--Aug. 23, 2017-- Omeros Corporation (NASDAQ:OMER) stated today that it continues to pursue legal action to hold responsible those behind a series of defamatory reports about the company posted online under the pseudonym “Art Doyle,” an entity or group that self-identifies
08/21/17 Omeros Closes $68.3 Million Public Offering of Common Stock
SEATTLE --(BUSINESS WIRE)--Aug. 21, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that on August 18, 2017 , as scheduled, it closed the underwritten public offering that was priced on August 14, 2017 , relating to the sale of 3,000,000 shares of its common stock at a price to the public
08/15/17 Omeros Announces Pricing of Public Offering of Common Stock
SEATTLE --(BUSINESS WIRE)--Aug. 15, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation,
08/14/17 Omeros Announces Public Offering of Common Stock
SEATTLE --(BUSINESS WIRE)--Aug. 14, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation,
08/14/17 Omeros Data Show Continued Improvement in Patients with IgA Nephropathy Treated with OMS721
– Sustained Proteinuria Reduction and GFR Improvement in up to One-Year Follow-up Data – SEATTLE --(BUSINESS WIRE)--Aug. 14, 2017-- Omeros Corporation  (NASDAQ: OMER) today announced additional follow-up data from patients with immunoglobulin A (IgA) nephropathy treated with OMS721 in the Phase 2
08/10/17 Omeros to Present at the 2017 Wedbush PacGrow Healthcare Conference
SEATTLE --(BUSINESS WIRE)--Aug. 10, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation,
08/08/17 Omeros Corporation Reports Second Quarter 2017 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Aug. 8, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
08/04/17 FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of IgA Nephropathy
- Initiating Phase 3 Program for OMS721 in IgA Nephropathy with Both Breakthrough and Orphan Designations - SEATTLE --(BUSINESS WIRE)--Aug. 4, 2017-- Omeros Corporation (NASDAQ:OMER) today announced that OMS721 has received orphan drug designation from the U.S.
08/02/17 Omeros Corporation to Announce Second Quarter 2017 Financial Results on August 8, 2017
SEATTLE --(BUSINESS WIRE)--Aug. 2, 2017-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter 2017 financial results for the period ended June 30, 2017 , on Tuesday, August 8, 2017 , after the market closes.
06/29/17 Omeros Releases Statement in Response to Recent False Report
SEATTLE --(BUSINESS WIRE)--Jun. 29, 2017-- Omeros Corporation (NASDAQ: OMER) stated today that it is aware of a report posted on-line by “Art Doyle,” an entity or group that appears to be concealing its identity and is purportedly writing on behalf of itself or one or more employers.
06/13/17 FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of IgA Nephropathy
- Omeros’ Second Phase 3 Clinical Program for OMS721 Slated to Begin this Year - SEATTLE --(BUSINESS WIRE)--Jun. 13, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that the US Food and Drug Administration ( FDA ) has granted breakthrough therapy designation to OMS721 for the treatment of
06/01/17 Omeros Announces OMS721 Presentation at 54th ERA-EDTA Congress
SEATTLE --(BUSINESS WIRE)--Jun. 1, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that data from the company’s Phase 2 clinical trial of OMS721 for the treatment of Immunoglobulin A (IgA) nephropathy and other kidney diseases will be presented at the 54th European Renal
05/17/17 Omeros Announces Completion of IgA Nephropathy Cohort in OMS721 Phase 2 Clinical Trial
-- Additional Positive Results Support Rapid Advancement to Phase 3 Trial -- SEATTLE --(BUSINESS WIRE)--May 17, 2017-- Omeros Corporation (NASDAQ: OMER) today announced completion of the IgA nephropathy cohort and reported additional positive results from the first stage of the company’s Phase 2
05/10/17 Omeros Corporation Reports First Quarter 2017 Financial Results
-- Conference Call Today at 4:30 p.m. ET -- SEATTLE --(BUSINESS WIRE)--May 10, 2017-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications
05/03/17 Omeros Corporation to Announce First Quarter 2017 Financial Results on May 10, 2017
SEATTLE --(BUSINESS WIRE)--May 3, 2017-- Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its first quarter 2017 financial results for the period ended March 31, 2017 , on Wednesday, May 10, 2017 , after the market closes.
04/03/17 Omeros to Present at the Needham Healthcare Conference
SEATTLE --(BUSINESS WIRE)--Apr. 3, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 16 th Annual Needham Healthcare Conference in New York City this week.
03/30/17 Omeros Reports More Positive Data in OMS721 Phase 2 Trial in Renal Diseases
-- Phase 3 Program Slated for This Year -- SEATTLE --(BUSINESS WIRE)--Mar. 30, 2017-- Omeros Corporation (NASDAQ: OMER) today announced additional positive data from the company’s Phase 2 clinical trial of OMS721 for the treatment of serious kidney disorders, which frequently lead to end-stage
03/28/17 Omeros Announces OMS721 Presentation at Annual Meeting of the European Society for Blood and Marrow Transplantation
-- Additional Positive “Challenge-Rechallenge” Data Reported in Patient with Stem Cell Transplant-Associated TMA -- SEATTLE --(BUSINESS WIRE)--Mar. 28, 2017-- Omeros Corporation (NASDAQ: OMER) today announced presentation of a case report describing resolution of hematopoietic stem cell
03/27/17 Omeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome at World Congress of Nephrology
SEATTLE, Wash. --(BUSINESS WIRE)--Mar. 27, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that data from the dose-ranging stage of the Phase 2 clinical trial evaluating OMS721 in the treatment of atypical hemolytic uremic syndrome (aHUS) will be presented next month at the International
03/16/17 Omeros Corporation Reports Fourth Quarter and Year-End 2016 Financial Results
-- Conference Call Today at 4:30 p.m. ET -- SEATTLE --(BUSINESS WIRE)--Mar. 16, 2017-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications
03/10/17 Omeros Corporation to Announce Fourth Quarter and Year-End 2016 Financial Results on March 16, 2017
SEATTLE --(BUSINESS WIRE)--Mar. 10, 2017-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end 2016 financial results for the period ended December 31, 2016 , on Thursday, March 16, 2017 , after the market closes.
03/02/17 Omeros to Present at the Cowen and Company Annual Health Care Conference
SEATTLE --(BUSINESS WIRE)--Mar. 2, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cowen and Company 37 th Annual Health Care Conference in Boston, MA next week.
03/01/17 Omeros Reports Additional Positive Results from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy
--Data Presented at the Recent Combined International and American Blood & Marrow Transplantation Meetings-- SEATTLE --(BUSINESS WIRE)--Mar. 1, 2017-- Omeros Corporation (NASDAQ: OMER) today announced additional positive data from the ongoing Phase 2 clinical trial evaluating OMS721 in the
12/07/16 Data from Omeros’ OMS721 Phase 2 Clinical Trial in Patients with Stem Cell Transplant-Associated TMA to be Presented at International Transplant Conference
-- Presentation Will Highlight Efficacy and Safety Results -- SEATTLE --(BUSINESS WIRE)--Dec. 7, 2016-- Omeros Corporation  (NASDAQ: OMER) today announced that an abstract highlighting positive results from the ongoing OMS721 Phase 2 clinical trial in patients with hematopoietic stem cell
12/06/16 Omeros Extending Compassionate Use for Pediatric Patient No Longer Requiring Dialysis after OMS721 Treatment
-- 15 Year-Old with Stem Cell Transplant-Associated TMA Had Previously Developed Additional Life-Threatening Condition while on Soliris ® -- SEATTLE --(BUSINESS WIRE)--Dec. 6, 2016-- Omeros Corporation  (NASDAQ: OMER) today announced that, following physician request, it will provide continued
12/05/16 Omeros’ Proprietary Orphan GPCR Program Delivers New Target and Approach in Cancer Immunotherapy
-- Small-Molecule Inhibitors Enhance Immune System and May Offer Advantages over Existing Cancer Therapies -- SEATTLE --(BUSINESS WIRE)--Dec. 5, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that its small-molecule inhibitors against GPR174, an orphan G protein-coupled receptor (GPCR)
11/30/16 International Consortium of Complement Experts Receives €1.3 Million Grant to Study Role of MASP-2 and Lectin Pathway in Traumatic Brain Injury
-- NEURON-Funded Program Will Evaluate Benefits of Omeros’ MASP-2 Antibody -- SEATTLE --(BUSINESS WIRE)--Nov. 30, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that an international consortium of complement experts from Italy , United Kingdom , Germany , Spain and Poland was awarded €1.3
11/21/16 Omeros Announces Successful Outcome of OMIDRIA® Pediatric Cataract Trial
-- Six-Month Extension of Patent Exclusivity and Label Expansion Expected -- SEATTLE --(BUSINESS WIRE)--Nov. 21, 2016-- Omeros Corporation (NASDAQ: OMER) today announced the successful outcome of its recently completed post-marketing clinical trial of the effect of OMIDRIA ® (phenylephrine and
11/10/16 Single Dose of Omeros’ Lead MASP-3 Inhibitor OMS906 Shows Multi-Week Blockade of the Alternative Pathway
-- Non-Human Primate Data Support Advancing to Clinic -- SEATTLE --(BUSINESS WIRE)--Nov. 10, 2016-- Omeros Corporation (NASDAQ: OMER) today announced pharmacokinetic and pharmacodynamic data from the evaluation of OMS906 in non-human primates. OMS906 inhibits mannan-binding lectin-associated serine
11/09/16 Omeros Corporation Reports Third Quarter 2016 Financial Results
-- Conference Call Today at 4:30 p.m. ET -- SEATTLE --(BUSINESS WIRE)--Nov. 9, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications
11/07/16 Omeros Corporation to Announce Third Quarter 2016 Financial Results on November 9, 2016
SEATTLE --(BUSINESS WIRE)--Nov. 7, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and
11/04/16 Omeros Announces Completion of Initial Funding under $125 Million Credit Facility
SEATTLE --(BUSINESS WIRE)--Nov. 4, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that it has completed the initial funding under its senior secured credit facility with affiliates of CRG LP , a healthcare-focused investment firm, consisting of an $80 million term loan.
11/03/16 Omeros Files Orphan Drug Application for OMS721 in Immunoglobulin A Nephropathy
-- Omeros Continues to Expand Orphan Indications for OMS721 -- SEATTLE --(BUSINESS WIRE)--Nov. 3, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that it has filed an application for orphan drug designation with the U.S. Food and Drug Administration ( FDA ) for OMS721 in the treatment of
11/02/16 Omeros Announces Positive Data from Phase 2 Clinical Trial Evaluating PPAR-Gamma Agonist in Heroin Users Treated with Buprenorphine/Naloxone
– Decreases Craving and Anxiety in Heroin-Dependent Patients – SEATTLE --(BUSINESS WIRE)--Nov. 2, 2016-- Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2 clinical trial evaluating the effects of a peroxisome proliferator-activated receptor (PPAR)-gamma agonist in
10/31/16 Omeros Requests Fast Track Designation for OMS721 for the Treatment of IgA Nephropathy
-- Phase 3 Clinical Program Planned for 2017 -- SEATTLE --(BUSINESS WIRE)--Oct. 31, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that it has requested fast track designation from the U.S. Food and Drug Administration ( FDA ) for the development of OMS721 for the treatment of patients
10/27/16 Omeros Announces $125 Million New Credit Facility
SEATTLE --(BUSINESS WIRE)--Oct. 27, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that it has entered into a senior credit facility with CRG LP , a healthcare-focused investment firm, to retire the company’s existing credit facility, minimizing restricted cash requirements and providing
10/20/16 Omeros Announces Positive Data from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy
-- Targeted Indications for the Company’s MASP-2 Inhibitor Continue to Expand -- SEATTLE --(BUSINESS WIRE)--Oct. 20, 2016-- Omeros Corporation  (NASDAQ: OMER) today announced positive results in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) from
10/19/16 Omeros Announces Positive Data from Phase 2 Clinical Trial Evaluating PPAR-gamma Agonist in Cocaine Abuse
-- Decreases Craving and Protects Brain White Matter Integrity -- SEATTLE --(BUSINESS WIRE)--Oct. 19, 2016-- Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2 clinical trial evaluating the effects of a peroxisome proliferator-activated receptor (PPAR)-gamma agonist
10/17/16 Omeros Announces Positive Data from OMS721 Phase 2 Clinical Trial in Renal Diseases
-- Pursuing Breakthrough Therapy Designation in IgA Nephropathy (Berger’s Disease) -- SEATTLE --(BUSINESS WIRE)--Oct. 17, 2016-- Omeros Corporation (NASDAQ: OMER) today announced positive data from the company’s Phase 2 clinical trial of OMS721 for the treatment of kidney disorders, none of which
09/08/16 Omeros’ MASP-2 Antibody Preserves Brain Tissue and Function in Stroke Models
-- Data Published in Journal of Neuroinflammation -- SEATTLE --(BUSINESS WIRE)--Sep. 8, 2016-- Omeros Corporation (NASDAQ: OMER) today announced results from its OMS721 complement program. OMS721 is Omeros’ lead antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2).
08/12/16 Omeros to Present at the 2016 Wedbush PacGrow Healthcare Conference
SEATTLE --(BUSINESS WIRE)--Aug. 12, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and
08/11/16 Omeros Announces Pricing of Public Offering of Common Stock
SEATTLE , Aug. 11, 2016 /PRNewswire/ --  Omeros Corporation  (NASDAQ: OMER) announced today the pricing of a $40 million underwritten public offering of its common stock at a price to the public of $11.50 per share, before deducting underwriting discounts and commission and other estimated offering
08/10/16 Omeros Announces Public Offering of Common Stock
SEATTLE , Aug. 10, 2016 /PRNewswire/ --  Omeros Corporation  (NASDAQ: OMER) today announced an agreement to sell $40 million of shares of its common stock to Cantor Fitzgerald & Co. , as the sole underwriter, in a registered underwritten public offering.
08/10/16 Omeros’ Lead MASP-3 Inhibitor OMS906 Demonstrates Efficacy in Paroxysmal Nocturnal Hemoglobinuria Model
-- Shows Substantial Advantage over C5 Inhibitor -- SEATTLE --(BUSINESS WIRE)--Aug. 10, 2016-- Omeros Corporation (NASDAQ: OMER) today announced results from its OMS906 complement program. OMS906 is Omeros’ lead antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3).
08/09/16 Omeros Corporation Reports Second Quarter 2016 Financial Results
-- Conference Call Today at 4:30 p.m. ET -- SEATTLE --(BUSINESS WIRE)--Aug. 9, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications
08/04/16 Omeros Corporation to Announce Second Quarter 2016 Financial Results on August 9, 2016
SEATTLE --(BUSINESS WIRE)--Aug. 4, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and
08/04/16 Omeros’ Lead MASP-3 Inhibitor OMS906 Demonstrates Blockade of the Alternative Pathway of Complement System
-- Shows Marked Efficacy in Model of Arthritis -- SEATTLE --(BUSINESS WIRE)--Aug. 4, 2016-- Omeros Corporation (NASDAQ: OMER) today announced results from its OMS906 complement program. OMS906 is Omeros’ lead antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the
07/28/16 Omeros Corporation Confirms OMS721 Phase 3 Development Plan with European Medicines Agency
-- One Single-Arm, Open-Label Phase 3 Pivotal Trial Planned to Support Approval in Both Europe and the U.S. -- SEATTLE , July 28, 2016 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has received scientific advice from the European Medicines Agency (EMA) in connection with
07/07/16 Omeros to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
SEATTLE --(BUSINESS WIRE)--Jul. 7, 2016-- Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and
06/29/16 Omeros Corporation Announces Completion of Patient Enrollment in Pediatric Trial of OMIDRIA®
-- Successful Completion Expected to Lead to Additional Market Exclusivity -- SEATTLE --(BUSINESS WIRE)--Jun. 29, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for
05/17/16 Omeros Announces Debt Financing Transaction for $20 Million in Additional Funds
SEATTLE --(BUSINESS WIRE)--May 17, 2016-- Omeros Corporation (NASDAQ: OMER) (the “Company”) today announced that it has entered into an amendment to its existing credit facility with Oxford Finance LLC (“Oxford”) and East West Bank (“East West”) to provide the Company with an additional $20 million
05/10/16 Omeros Corporation Reports First Quarter 2016 Financial Results
-- Conference Call Today at 9:00 a.m. ET -- SEATTLE --(BUSINESS WIRE)--May 10, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications
05/10/16 Leonard M. Blum Joins Omeros to Lead Business and Commercial Activities
SEATTLE --(BUSINESS WIRE)--May 10, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and
05/10/16 Omeros Corporation Announces Exclusive Middle East Distribution Agreement for OMIDRIA®
-- Initiates International Market Expansion -- SEATTLE --(BUSINESS WIRE)--May 10, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan
05/04/16 Omeros Corporation to Announce First Quarter 2016 Financial Results on May 10, 2016
SEATTLE --(BUSINESS WIRE)--May 4, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and
04/26/16 Omeros Corporation Announces Independent Studies with OMIDRIA® to Be Presented at Upcoming Ophthalmology Congresses
-- Studies Assessed Key Surgical Outcome Measures Including Complication Rates -- SEATTLE --(BUSINESS WIRE)--Apr. 26, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for
04/20/16 Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases
-- Study Provides an Opportunity for Breakthrough Therapy Designation and Subsequent Accelerated Approval -- SEATTLE --(BUSINESS WIRE)--Apr. 20, 2016-- Omeros Corporation  (NASDAQ: OMER) today announced initiation of patient dosing in its OMS721 Phase 2 program in corticosteroid-dependent renal
04/07/16 Omeros to Present at the 15th Annual Needham Healthcare Conference
SEATTLE --(BUSINESS WIRE)--Apr. 7, 2016-- Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and
03/08/16 Omeros Corporation Initiates its Phase 3 Program for OMS721 in aHUS Following Meeting with FDA
-- Single Pivotal Study Needed for Phase 3 -- SEATTLE --(BUSINESS WIRE)--Mar. 8, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications
03/07/16 Omeros Corporation Reports Fourth Quarter and Year-End 2015 Financial Results
Conference Call Tomorrow, March 8 , at 9:00 a.m. ET SEATTLE --(BUSINESS WIRE)--Mar. 7, 2016-- Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan
03/03/16 Omeros to Present at the Cowen and Company 36th Annual Health Care Conference
SEATTLE --(BUSINESS WIRE)--Mar. 3, 2016--   Omeros Corporation   (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies
03/02/16 Omeros Corporation to Announce Fourth Quarter and Year-End 2015 Financial Results on March 8, 2016
SEATTLE --(BUSINESS WIRE)--Mar. 2, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and
02/24/16 Physicians Increasingly Seek Access to OMS721 Compassionate Use Program
-- OMS721 Requested for Finnish Patient Not Adequately Responsive to Soliris ® -- SEATTLE --(BUSINESS WIRE)--Feb. 24, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for
01/16/16 Disclosure of Omidria Post-Launch Study Findings to Occur at Hawaiian Eye and Retina Conference
SEATTLE --(BUSINESS WIRE)--Jan. 15, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications targeting inflammation, coagulopathies and
01/06/16 Omeros Announces $70 Million New Credit Facility and Conversion of Contract Sales Force to In-House Team
SEATTLE --(BUSINESS WIRE)--Jan. 6, 2016-- Omeros Corporation (NASDAQ:OMER) today announced that it has closed a non-dilutive senior credit facility with Oxford Finance and East West Bank . The new credit facility consists of a $50.0 million term loan drawn by the company at closing and the ability,
11/09/15 Omeros Corporation Reports Third Quarter 2015 Financial Results
-- Conference Call Today at 4:30 p.m. ET -- SEATTLE , Nov. 9, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications
11/02/15 Omeros Corporation to Announce Third Quarter 2015 Financial Results on November 9, 2015
SEATTLE , Nov. 2, 2015 /PRNewswire/ --   Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and
10/15/15 Omeros Announces OMIDRIAssure™ to Expand Patient Access to Omidria®
-- Ensures Access to Benefits of Omidria for Cataract Patients, Surgeons and Facilities -- SEATTLE , Oct. 15, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has launched OMIDRIAssure ™ , a comprehensive reimbursement services program to provide expanded access to
09/03/15 Omeros Files Infringement Suits Against Par
SEATTLE , Sept. 3, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has filed patent infringement lawsuits against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC , (collectively "Par") in the U.S.
08/18/15 Omeros Announces Additional Positive Data in OMS721 Phase 2 Clinical Trial
-- Company Plans for Phase 3 Program Based on Consistent Response in TMA Patients -- SEATTLE , Aug. 18, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies
08/17/15 Omeros Announces Plan to File Infringement Suit Against ANDA Filer
SEATTLE , Aug. 17, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today, in response to investor questions, announced that it plans to file a patent infringement lawsuit against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC (Par) in response to the Abbreviated New
08/10/15 Omeros Corporation Reports Second Quarter 2015 Financial Results
-- Conference Call Today at 4:30 p.m. ET -- SEATTLE , Aug. 10, 2015 /PRNewswire/ --   Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications
08/07/15 Omeros to Present at the 2015 Wedbush PacGrow Healthcare Conference
SEATTLE , Aug. 7, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
08/03/15 Omidria® Approved for Commercialization Throughout the European Union and Additional Countries
-- Approval by the European Commission Follows Unanimous Recommendation by the EMA -- SEATTLE , Aug. 3, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that the European Commission (EC) has granted marketing authorization for Omidria (phenylephrine and ketorolac injection)
07/31/15 Omeros Corporation to Announce Second Quarter 2015 Financial Results on August 10, 2015
SEATTLE , July 31, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and
07/23/15 FDA Grants "Fast Track" to Omeros' Complement Inhibitor OMS721 for aHUS
-- Phase 2 Trial and Compassionate Use Program Advance -- SEATTLE , July 23, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration ( FDA ) granted Fast Track designation to OMS721 for the treatment of patients with atypical hemolytic
06/17/15 Rajiv Shah, M.D., Appointed to Omeros' Board of Directors
SEATTLE , June 17, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that Rajiv Shah , M.D., recent Administrator of the United States Agency for International Development (USAID), has been appointed to serve on the company's board of directors. From 2010 to 2015, Dr.
06/16/15 Omeros Announces Exclusive License Agreement for Omeros' Arthroscopic Product OMS103
-- U.S. Sales to Begin This Year -- SEATTLE , June 16, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications, today
05/22/15 Omidria® Receives Positive Opinion from European Medicines Agency's Committee for Medicinal Products for Human Use
- Unanimous Recommendation to Grant European Marketing Authorization for Omidria Based on Benefit/Risk Profile - SEATTLE , May 22, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein
05/11/15 Omeros Corporation Reports First Quarter 2015 Financial Results
-- Omidria Now Widely Available in the U.S. Following Commercial Launch -- SEATTLE , May 11, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as
05/05/15 Omeros Corporation to Announce First Quarter 2015 Financial Results on May 11, 2015
SEATTLE , May 5, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and
04/14/15 European Regulatory Authority Approves Clinical Investigator's Request for Compassionate Use with Omeros Corporation's OMS721
-- Patients with Thrombotic Microangiopathy Will Now Be Able to Receive Extended Treatment - SEATTLE , April 14, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that the presiding European regulatory authority has approved the company's investigational product OMS721 for
04/09/15 Omeros to Present at the 14th Annual Needham Healthcare Conference
SEATTLE , April 9, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and
04/02/15 Omeros Corporation Announces the U.S. Commercial Launch of Omidria™
-- First and Only FDA-Approved Intraocular Product that Prevents Pupil Constriction and Reduces Postoperative Pain -- SEATTLE , April 2, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and
03/16/15 Omeros Corporation Reports Fourth Quarter and Year-End 2014 Financial Results
-- 4Q 2014 net loss of $20.7 million, or $0.61 per share -- SEATTLE , March 16, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
03/09/15 Omeros Corporation to Announce Fourth Quarter and Full-Year 2014 Financial Results on March 16, 2015
SEATTLE , March 9, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and
02/19/15 Omeros Corporation's Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use
- The Company Agrees to Physician Request to Continue Treatment of Patients with aHUS - SEATTLE , Feb. 19, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has completed dosing of the low-dose cohort of patients in its ongoing Phase 2 clinical trial evaluating the
02/03/15 Omeros Closes $84 Million Public Offering of Common Stock and Pre-Funded Warrants
SEATTLE , Feb. 3, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors on January 28, 2015 relating to the sale of 3,444,831 shares of its common stock at a price of $20.03 per share
01/29/15 Omeros Prices $75 Million Public Offering of Common Stock and Pre-Funded Warrants
SEATTLE , Jan. 29, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has priced an underwritten public offering of 2,995,506 shares of its common stock at a per share price to the public equal to $20.03 , and pre-funded warrants to purchase up to 749,250 shares of its
01/28/15 Omeros Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SEATTLE , Jan. 28, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced its intention to offer, subject to market and other conditions, shares of its common stock and pre-funded warrants to purchase shares of its common stock in a registered underwritten public offering.
11/19/14 OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients
- Data Bode Well for Success of Ongoing Phase 2 Trial in Thrombotic Microangiopathies - SEATTLE , Nov. 19, 2014 /PRNewswire/ --   Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine
11/10/14 Omeros Corporation Reports Third Quarter 2014 Financial Results
-- Omidria™ U.S. Commercial Launch Planned for Early 2015 -- SEATTLE , Nov. 10, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
11/06/14 Omeros Announces Positive Data for MASP-2 Inhibitor in Experimental Model of Stroke
-- Lectin Pathway Identified as Key Contributor to Stroke Sequelae -- SEATTLE , Nov. 6, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data using a derivative of OMS721 in a well-established animal model of stroke. OMS721 is the company's lead human monoclonal
11/04/14 Omeros Corporation to Announce Third Quarter 2014 Financial Results on November 10, 2014
SEATTLE , Nov. 4, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders
10/30/14 Omidria™ Granted Pass-Through Reimbursement Status from CMS
-- Unique Billing Code Allows Separate Payment for Omidria -- SEATTLE , Oct. 30, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) announced today that it has received transitional pass-through status for its lead product Omidria ™ (phenylephrine and ketorolac injection) 1%/0.3% from the
10/21/14 Omeros Provides Update on PDE10 Inhibitor Program
-- Enrollment in Huntington's Trial Suspended Pending Further Assessment of Preclinical Data -- SEATTLE , Oct. 21, 2014 /PRNewswire/ --   Omeros Corporation (NASDAQ: OMER) today provided an update on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of
08/11/14 Omeros Corporation Reports Second Quarter 2014 Financial Results
-- FDA Approval of Omidria™ Received on May 30, 2014 - SEATTLE , Aug. 11, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
08/08/14 Omeros to Present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference
SEATTLE , Aug. 8, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
06/02/14 Omeros Receives FDA Approval of Omidria™ for Use in Cataract and Other Intraocular Lens Replacement Procedures
-- Omeros to Host Conference Call Today at 4:30 p.m. ET -- SEATTLE , June 2, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration ( FDA ) has approved Omidria™ (phenylephrine and ketorolac injection) 1%/0.3% for use during cataract
05/12/14 Omeros Corporation Reports First Quarter 2014 Financial Results
-- Secures Additional $50.4 Million in Cash in 1Q 2014 -- SEATTLE , May 12, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation,
04/07/14 Omeros to Present at the 13th Annual Needham Healthcare Conference
SEATTLE , April 7, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
04/03/14 Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies
-- Phase 2 Clinical Trial Planned to Begin This Quarter -- SEATTLE , April 3, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement‑mediated thrombotic microangiopathies (TMAs)
04/01/14 Omeros Invited to Present on OMS824 Phase 2 Clinical Program at the Schizophrenia International Research Conference
-- Conference Focuses on New Drug Development and Cutting Edge Research in Schizophrenia -- SEATTLE , April 1, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that the company was invited by the organizers of the 2014 Biennial Conference of the Schizophrenia International
03/21/14 Omeros to Present at BioCentury Future Leaders in the Biotech Industry Conference
SEATTLE , March 21, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
03/19/14 Omeros Closes $40.25 Million Public Offering of Common Stock
SEATTLE , March 19, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors prior to the opening of the market on March 14, 2014 , relating to the sale of 3,500,000 shares of its common
03/14/14 Omeros Prices $35.0 Million Public Offering of Common Stock
SEATTLE, March 14, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has priced an underwritten public offering of 3,043,479 shares of its common stock at a price to the public of $11.50 per share for gross proceeds of $35.0 million .
03/13/14 Omeros Announces Proposed Public Offering of Common Stock
SEATTLE , March 13, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced its intention to offer, subject to market and other conditions, shares of its common stock in a registered underwritten public offering. Omeros also expects to grant the underwriters a 30-day option to
03/13/14 Omeros Corporation Reports Fourth Quarter and Year-End 2013 Financial Results
-- 4Q 2013 net loss of $1.8 million, or $0.05 per share -- SEATTLE , March 13, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation,
03/10/14 Omeros Announces Positive OMS721 Data in Serum from Patients with aHUS
- Phase 2 Clinical Trial in aHUS and Other TMAs Expected to Begin Next Quarter - SEATTLE , March 10, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2
03/06/14 Omeros Reports Additional Positive Data from its OMS824 Phase 2a Schizophrenia Clinical Trial
-- Significantly Higher Drug Exposure Achieved with Continued Tolerability -- SEATTLE , March 6, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced additional positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor.
03/05/14 Omeros Closes $32 Million Debt Financing, Receiving $12.6 Million in New Funds
SEATTLE , March 5, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has closed a senior credit facility with Oxford Finance and MidCap Financial, which is expected to fund later today. The new credit facility consists of a $32 million term loan, which requires
03/04/14 Omeros Submits IND to Advance OMS721 Phase 2 Clinical Program
-- Successful Phase 1 Results Set the Stage for Trials in Patients with Life-Threatening Blood Disorders -- SEATTLE , March 4, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has submitted to the U.S. Food and Drug Administration ( FDA ) an investigational new drug
02/26/14 Omeros to Present at Cowen and Company 34th Annual Health Care Conference
SEATTLE , Feb. 26, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
02/19/14 Omeros Announces Enrollment in Second Phase 2 Clinical Trial with OMS824
-- PDE10 Inhibitor Administered to Patients with Huntington's Disease -- SEATTLE , Feb. 19, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being
02/11/14 Omeros Reports Additional Positive Phase 1 Clinical Data for OMS824 for the Treatment of Cognitive Disorders
-- PDE10 Target Engagement Continues to Increase with Well-Tolerated Doses -- SEATTLE , Feb. 11, 2014 /PRNewswire/ -- Omeros Corporation  (NASDAQ: OMER) today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program.
02/05/14 FDA Grants Fast Track Designation to Omeros' OMS824 Huntington's Disease Program
-- Enrollment in Huntington's Phase 2 Trial Expected Soon -- SEATTLE , Feb. 5, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration ( FDA ) granted Fast Track designation to OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor,
02/03/14 Omeros Announces Positive Data after Completion of Dosing in Phase 1 Clinical Trial with OMS721
-- Phase 2 Program Expected to Initiate this Quarter -- SEATTLE , Feb. 3, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data following completion of dosing in a Phase 1 clinical trial of OMS721, the company's lead human monoclonal antibody targeting mannan-binding
01/29/14 Omeros Reports Positive Results from OMS824 Phase 2a Clinical Trial
- Data expand potential indications both within schizophrenia and to other neuropsychiatric disorders - SEATTLE , Jan. 29, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10)
12/18/13 FDA Grants Orphan Drug Designation to Omeros' OMS721 for Complement-Mediated Thrombotic Microangiopathies
-- Phase 2 Program Expected to Begin Next Quarter -- SEATTLE , Dec. 18, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the
12/05/13 Omeros to Present at Oppenheimer 24th Annual Healthcare Conference
SEATTLE , Dec. 5, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
11/20/13 Omeros Announces FDA Acceptance of Omidria™ as Proprietary Name for OMS302
-- European Medicines Agency Review of Proposed Names to be Completed Soon -- SEATTLE , Nov. 20, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported that the U.S. Food and Drug Administration ( FDA ) accepted the proposed brand name Omidria™ for OMS302, the Company's proprietary
11/19/13 Omeros Reports Phase 3 OMS302 Clinical Data Presented at the Annual American Academy of Ophthalmology Meeting
-- In These Clinical Trials, OMS302 Reduced Incidence of Miosis -- SEATTLE , Nov. 19, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular
11/12/13 Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American Academy of Ophthalmology Annual Meeting
-- OMS302 also to be Featured in "Cutting Edge" Symposium -- SEATTLE , Nov. 12, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it will present data from its Phase 3 clinical program for OMS302 at the American Academy of Ophthalmology (AAO) Annual Meeting, which will
11/07/13 Omeros Announces Positive Data in Phase 1 Clinical Trial with OMS721
-- Phase 2 Program Expected to Begin Enrollment Next Quarter -- SEATTLE , Nov. 7, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive clinical data in a Phase 1 clinical trial of OMS721, the company's lead human monoclonal antibody targeting mannan-binding
11/07/13 Omeros Corporation Reports Third Quarter 2013 Financial Results
-- Obtains Additional $17.4 Million in Cash in 4Q 2013 -- SEATTLE, Wash. , Nov. 7, 2013 /PRNewswire/ -- Received $17.4 million in cash in October 2013 Total operating expenses in 3Q 2013 were $13.6 million including $3.2 million in non-cash expenses compared to $13.3 million including non-cash
11/05/13 Omeros Announces Positive OMS721 Data in Model of Age-Related Macular Degeneration
-- Ongoing Clinical Program for OMS721 Continues to Advance -- SEATTLE , Nov. 5, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program, in
10/17/13 Omeros Corporation Files Universal Shelf Registration Statement to Replace Expiring Universal Shelf Registration Statement
SEATTLE , Oct. 17, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has filed a replacement universal shelf registration statement (the "2013 Registration Statement") with the Securities and Exchange Commission (the " SEC ").
10/17/13 Omeros Reports Additional Positive Clinical Data for its Drug Candidate to Treat Cognitive Disorders
-- PDE10 Target Engagement Continues to Increase with Well-Tolerated Doses - SEATTLE , Oct. 17, 2013 /PRNewswire/ --   Omeros Corporation (NASDAQ: OMER) today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program.
10/15/13 FDA Agrees with Omeros' Pediatric Study Plan for OMS302
-- Completion of Pediatric Study Can Lead to Additional Marketing Exclusivity - SEATTLE , Oct. 15, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration ( FDA ) confirmed its agreement with the Pediatric Study Plan (PSP) proposed by
10/08/13 Omeros Hires Michael K. Inouye to Lead Commercial Operations
SEATTLE , Oct. 8, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company with marketing applications for its lead product OMS302 for use during lens replacement surgery currently under review in both the US and Europe , today announced the appointment of
10/03/13 Omeros Settles Insurance Litigation
-- Omeros to Receive $12.5 Million -- SEATTLE , Oct. 3, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) announced today that it entered into a settlement agreement with its insurer, Carolina Casualty Insurance Company (CCIC), related to CCIC's defense of, and coverage obligations owed to,
10/03/13 Omeros Unlocks Six Additional Class A Orphan GPCRs and Identifies Small Molecules Targeting Two Commercially Validated Class B GPCRs
-- Brings Omeros' Total to 52 Class A Orphans and Opens Way to New Oral Drugs to Treat Diabetes and Osteoporosis -- SEATTLE , Oct. 3, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that functionally interact with each of six additional
10/02/13 US and European Regulators Accept for Review OMS302 Marketing Applications
-- OMS302 Remains on Track for Planned 2014 Commercial Launch -- SEATTLE , Oct. 2, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) announced today that the New Drug Application (NDA) for its ophthalmology product, OMS302, has been confirmed for filing by the U.S.
09/30/13 FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease
-- Phase 2 Clinical Trial in Huntington's Disease Slated to Begin This Year -- SEATTLE , Sept. 30, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) announced that OMS824, its phosphodiesterase 10 (PDE10) inhibitor, has received orphan drug designation from the U.S.
09/20/13 Omeros Chosen to Present at NewsMakers in the Biotech Industry 2013 Conference
SEATTLE , Sept. 20, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
09/19/13 Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
-- PDE10 Inhibitor Administered to Patients with Schizophrenia -- SEATTLE , Sept. 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ:OMER) today announced initiation of enrollment in a Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor.
09/12/13 Omeros Reports Additional Positive Results from OMS824 Program
-- Phase 1 Trial Data Predict Substantially Greater Target Engagement with Better Tolerability Than Seen with Other PDE10 Inhibitors -- SEATTLE , Sept. 12, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data from the Company's Phase 1 clinical trial evaluating the
09/10/13 Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
- European Market Launch Planned for Second Half of 2014 - SEATTLE , Sept. 10, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market OMS302 for
09/09/13 Omeros to Present at the Stifel Healthcare Conference 2013
SEATTLE , Sept. 9, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
08/13/13 Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
SEATTLE , Aug. 13, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, has announced that Michael A.
08/09/13 Omeros Corporation Reports Second Quarter 2013 Financial Results
SEATTLE , Aug. 9, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial
08/08/13 Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
SEATTLE , Aug. 8, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it will present at the Wedbush
08/01/13 Omeros Submits New Drug Application to U.S. FDA for OMS302
- Submission of European Marketing Authorization Application Planned for this Quarter - SEATTLE , Aug. 1, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) announced that the company recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for approval of
07/02/13 European Medicines Agency Approves Positive Opinion on Omeros' Pediatric Investigation Plan for OMS302
-- Submission of Marketing Authorization Application Remains on Track for Mid-Year-- SEATTLE , July 2, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that the European Medicines Agency (EMA) approved a positive opinion issued by the European Pediatrics Committee (PDCO)
06/13/13 Omeros Obtains Regulatory Approval to Initiate Phase 1 Clinical Trial for Lead Antibody in MASP-2 Program
-- Enrollment Expected to Begin Next Month -- SEATTLE , June 13, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its
05/31/13 Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
-- OMS824 Achieves High Target Occupancy without Causing Movement Disorders Seen with Other PDE10 Inhibitors -- SEATTLE , May 31, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced positive results from its Phase 1 clinical program evaluating OMS824, the lead compound from its
05/28/13 Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
-- Phase 1 Clinical Trial Expected to Begin Early Next Quarter -- SEATTLE, Wash. , May 28, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed a Clinical Trial Application (CTA) with European regulators to initiate clinical trials evaluating OMS721, the
05/23/13 Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease
-- Clinical Trial in Patients with Huntington's Disease Slated to Begin Next Quarter -- SEATTLE , May 23, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS824 in Huntington's disease has been cleared by the
05/22/13 Omeros to Present at Two Upcoming Conferences
SEATTLE , May 22, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
05/14/13 Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
SEATTLE , May 14, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported that it closed the registered direct offering of 3,903,004 shares of its common stock that was announced on May 9 , 2013.  The shares were sold at a price of $4.14 per share, which represented a two percent
05/10/13 Omeros Corporation Reports First Quarter 2013 Financial Results
SEATTLE , May 10, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial
05/09/13 Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
SEATTLE , May 9, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has agreed to sell 3,903,004 shares of its common stock at a price of $4.14 per share, a two percent premium over the closing price on May 8, 2013 , for gross proceeds of $16.2 million .
05/01/13 Omeros Requests Fast Track Designation for OMS824 for the Treatment of Huntington's Disease
-- Phase 2 Clinical Trial Slated to Begin This Year -- SEATTLE , May 1, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has requested Fast Track Designation from the U.S. Food and Drug Administration ( FDA ) for the development of OMS824 for the treatment of
04/30/13 Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
-- Centralized Procedure Used for Products that Represent Therapeutic Innovation -- SEATTLE , April 30, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that the European Medicines Agency (EMA) has confirmed that the Company's planned Marketing Authorization Application (MAA)
04/25/13 Omeros Reports OMS302 Clinical Data Presented at the Annual ASCRS and ASOA Symposium and Congress
-- Data Show that OMS302 Maintains Pupil Size During Lens Replacement Surgery by Not Only Promoting Mydriasis but also by Preventing Miosis -- SEATTLE , April 25, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported analyses of Phase 2 and Phase 3 clinical data showing the
04/24/13 Omeros to Present at the 12th Annual Needham Healthcare Conference
SEATTLE , April 24, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it will present at the 12 th
04/19/13 Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
SEATTLE , April 19, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it will present additional data from recent clinical trials evaluating its ophthalmology product, OMS302, at the Annual American Society of Cataract and Refractive Surgery and American Society of
04/17/13 Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721
-- Orphan Drug Designation Could Provide Financial Incentives and Faster Regulatory Review -- SEATTLE , April 17, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed an Application for Orphan Drug Designation with the U.S.
04/10/13 Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
- Adds to Earlier Data Demonstrating Potential to Restore Myelin in MS Patients - SEATTLE , April 10, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS),
04/02/13 Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
-- Support Advancing Initial Clinical Indication of Atypical Hemolytic Uremic Syndrome -- SEATTLE , April 2, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros ' mannan-binding lectin-associated serine
03/29/13 Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
SEATTLE , March 29, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it has been chosen to present
03/28/13 Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
-- European Clinical Trial Application Submission Expected in the Second Quarter of 2013 -- SEATTLE , March 28, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced data from toxicology studies evaluating OMS721, the lead human monoclonal antibody in Omeros ' mannan-binding
03/26/13 Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
-- Data Predict OMS824 has Greater Brain Activity without Movement Side-Effects Seen with other PDE10 Inhibitors -- SEATTLE , March 26, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data from the multiple-ascending-dose (MAD) portion of the Company's Phase 1
03/19/13 Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
-- Clinical Entry Planned for Second Half of 2013 -- SEATTLE , March 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has elucidated the mechanism of action of its phosphodiesterase 7 (PDE7) inhibitors in the neural network shown to be responsible for addiction in
03/18/13 Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
SEATTLE , March 18, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial
03/01/13 Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
SEATTLE , March 1, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
02/07/13 Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
-- IND/CTA Submission Expected in the Second Quarter of 2013 -- SEATTLE , Feb. 7, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced data from toxicology studies evaluating OMS721, the lead human monoclonal antibody in Omeros ' mannan-binding lectin associated serine protease-2
01/22/13 Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
-- Market Launch Expected First Half of 2014 -- SEATTLE , Jan. 22, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced the successful completion of the 90-day safety database lock in the second of the Company's two pivotal Phase 3 clinical trials evaluating OMS302 in patients
01/16/13 Omeros Identifies Small Molecules for Class B GPCR
- Expands "Unlocking" Capability Beyond Class A Orphan GPCRs - SEATTLE , Jan. 16, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its proprietary Cellular Redistribution Assay (CRA) technology, which to date has successfully "unlocked" 46 of the 80 total Class A orphan G
12/27/12 Omeros Reports OMS103HP Phase 3 Clinical Trial Results
-- Second Meniscectomy Phase 3 Clinical Trial Enrollment Targeted for First Half of 2013 -- -- Company to Host Conference Call Today at 5:00 p.m. EST -- SEATTLE , Dec. 27, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported results from its first pivotal Phase 3 clinical trial
12/06/12 Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
-- Single-Ascending-Dose Study Results Support Continued Advancement of Phase 1 Trial-- SEATTLE , Dec. 6, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced promising data from the single-ascending-dose (SAD) study portion of the Company's Phase 1 clinical trial evaluating
11/29/12 Omeros Appoints Thomas A. Mitro as Vice President, Sales and Marketing
SEATTLE , Nov. 29, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced the
11/20/12 Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
SEATTLE , Nov. 20, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A.
11/15/12 GPR17-Targeting Compounds Identified by Omeros Promote Myelination
-Remyelination May Provide a Novel Treatment for Multiple Sclerosis Patients- SEATTLE , Nov. 15, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that GPR17-targeting compounds, which were previously identified by Omeros in connection with unlocking this orphan receptor, have
11/13/12 Omeros is Not Aware of Any Justification for Share Price Movement
SEATTLE , Nov. 13, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) has noted the fall in its share price over the last week of trading.  Omeros is not aware of any reason that justifies this decrease. As disclosed in Omeros ' recent press releases and its Quarterly Report on Form 10-Q filed
11/09/12 Omeros Corporation Reports Third Quarter 2012 Financial Results
SEATTLE , Nov. 9, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial
11/09/12 Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
SEATTLE , Nov. 9, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today is addressing misleading statements in a press release issued yesterday by Davis Wright Tremaine , the law firm representing Richard J. Klein , Omeros ' former chief financial officer with whom Omeros recently settled a
11/08/12 Omeros to Present Data from Successful OMS302 Phase 3 Clinical Trial at the American Academy of Ophthalmology Annual Meeting
SEATTLE , Nov. 8, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported that it will present data from its first pivotal Phase 3 clinical trial evaluating OMS302 at the American Academy of Ophthalmology (AAO) Annual Meeting, which will take place from November 10 through November
11/05/12 Omeros' Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
-- Submission of New Drug Application Planned for First Half of 2013-- -- Company to Host Conference Call Today at 9:00 a.m. EST-- SEATTLE , Nov. 5, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported positive data from the second of its two pivotal Phase 3 clinical trials
11/01/12 Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
-- Data Expected Before Year End -- SEATTLE , Nov. 1, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the first subject has been enrolled in the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros ' phosphodiesterase 10 (PDE10) program. 
10/24/12 Adding Four More, Omeros Has Now Unlocked 46 Orphan GPCRs
-- Equals Number of GPCRs Targeted by over 30 Percent of Marketed Drugs -- SEATTLE , Oct. 24, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that functionally interact with each of four additional orphan G protein-coupled receptors (GPCRs).
10/18/12 Omeros Adds Vice Presidents of Regulatory and Clinical to Management Team
-Cathy Melfi, Ph.D. to Head Regulatory Function and Dr. Albert Yu to Serve as VP, Clinical Development- SEATTLE , Oct. 18, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting
10/03/12 Omeros Announces Completion of Enrollment in OMS302 Phase 3 Clinical Trial
-- Results Expected this Quarter -- SEATTLE , Oct. 3, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the last patient has been enrolled in the Company's second Phase 3 clinical trial evaluating OMS302 for use during intraocular lens replacement (ILR) surgery.
10/02/12 Investigational New Drug Application Cleared for Omeros' Lead Compound in PDE10 Program
-- Data from First Phase 1 Clinical Trial Expected in 2012 -- SEATTLE , Oct. 2, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the Company's OMS824 Investigational New Drug Application (IND) has been cleared by the U.S. Food and Drug Administration (FDA).  With this
09/27/12 Arnold C. Hanish Elected to Board of Directors of Omeros
SEATTLE , Sept. 27, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that its Board of Directors has elected Arnold C. Hanish to serve on the Company's Board. Mr. Hanish has also been appointed to serve as Chairman of the Audit Committee.
09/19/12 Omeros Awarded NIMH Grant for Development of Orphan GPCR Antibodies
-- Omeros' Proprietary Antibody Platform Enables Rapid Discovery -- SEATTLE , Sept. 19, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the National Institute of Mental Health (NIMH) awarded a grant to the Company for its proprietary antibody discovery (DTLacO) platform.
09/06/12 Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
-- Data from First Phase 1 Clinical Trial Expected in 2012 -- SEATTLE , Sept. 6, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration ( FDA ) to initiate clinical trials
09/04/12 Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
SEATTLE , Sept. 4, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
08/15/12 Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
-- Five Additional Orphans Connected to Autism, Osteoarthritis and Neuropsychiatric Disorders -- SEATTLE , Aug. 15, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that functionally interact with each of five additional orphan G
08/08/12 Omeros to Present at Two Upcoming Conferences
SEATTLE , Aug. 8, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
08/08/12 Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
-- On Track to Report Data Later this Year -- SEATTLE , Aug. 8, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported the completion of enrollment in the first of two planned Phase 3 clinical trials evaluating OMS103HP in patients undergoing arthroscopic partial meniscectomy
08/07/12 Omeros Corporation Reports Second Quarter 2012 Financial Results
SEATTLE , Aug. 7, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial
07/31/12 Omeros Announces Discovery in MASP-2 Program
-- Mechanism of Activation of Complement System's Alternative Pathway Identified -- SEATTLE , July 31, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported that it believes it has identified the proteins that activate the alternative pathway of the complement system, an important
07/18/12 Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
-- Omeros Has Notified FDA of Intent to Submit Investigational New Drug Application this Quarter -- SEATTLE , July 18, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported that OMS824, the lead compound in the Company's phosphodiesterase 10 (PDE10) program for schizophrenia, has
07/02/12 Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
SEATTLE , July 2, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors prior to the opening of the market on June 27, 2012 , relating to the sale of 3,365,854 shares of its common stock
06/27/12 Omeros Prices $30 Million Public Offering of Common Stock
SEATTLE , June 27, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has priced an underwritten public offering of 2,926,830 shares of its common stock at a price to the public of $10.25 per share for gross proceeds of $30.0 million .
06/26/12 Omeros Announces Proposed Public Offering of Common Stock
SEATTLE , June 26, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced its intention to offer, subject to market and other conditions, shares of its common stock in a registered underwritten public offering. Omeros also expects to grant the underwriters a 30-day option to
05/31/12 Omeros Announces Initiation of Planned Pharmacokinetic Substudy in OMS302 Phase 3 Clinical Program
-- 24-Patient Study to Confirm Low Levels of Systemic Exposure Observed in Preclinical Studies -- SEATTLE , May 31, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced the initiation of the planned pharmacokinetic (PK) substudy in its Phase 3 clinical program evaluating OMS302
05/29/12 Omeros to Present at Jefferies 2012 Global Healthcare Conference
SEATTLE , May 29, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
05/10/12 Omeros Corporation Reports First Quarter 2012 Financial Results
SEATTLE , May 10, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial
05/03/12 Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
-- Now Totaling 37, Omeros Has Unlocked Over 45 Percent of the Class A Orphan GPCRs -- SEATTLE , May 3, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that functionally interact with each of four additional orphan G protein-coupled receptors
05/02/12 Omeros to Present at Deutsche Bank Securities Health Care Conference
SEATTLE , May 2, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
04/10/12 Omeros Announces Enrollment in Second Phase 3 Clinical Trial Evaluating OMS302
--Data from Trial Expected in Second Half of 2012-- SEATTLE , April 10, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that patient enrollment has begun in the Company's second Phase 3 clinical trial evaluating OMS302 in intraocular lens replacement (ILR) surgery.
03/29/12 Omeros Reports Allowance of Additional Patent for Ophthalmology Product OMS302
SEATTLE , March 29, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported the allowance by the US Patent and Trademark Office (USPTO) of an additional patent claiming intraocular surgical methods of using OMS302, the Company's ophthalmological PharmacoSurgery™ product.
03/28/12 Omeros to Present at Two Upcoming Conferences
SEATTLE , March 28, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
03/27/12 Omeros Names Dr. Patrick Gray as Scientific Fellow
SEATTLE , March 27, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced the
03/15/12 Omeros Corporation Reports Fourth Quarter and Year-End 2011 Financial Results
SEATTLE , March 15, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial
03/13/12 Omeros' Ophthalmology Product OMS302 Achieves Primary and Secondary Endpoints in Phase 3 Clinical Trial
-- Company to Host Conference Call Today at 9:00 a.m. EDT-- SEATTLE , March 13, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported positive data from its Phase 3 clinical trial evaluating OMS302 in patients undergoing intraocular lens replacement surgery.  OMS302 met its primary
03/01/12 Omeros to Present at the Cowen and Company 32nd Annual Health Care Conference
SEATTLE , March 1, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory
02/29/12 Adding Six More, Omeros Now Has a Total of 33 Unlocked Orphan GPCRs in its Portfolio
-- Latest Receptors Linked to Multiple Sclerosis, Schizophrenia, Rheumatoid Arthritis, Cancer Stem Cells, Bone Disorders, New Hair Follicle Generation and Wound Repair -- SEATTLE , Feb. 29, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that
02/23/12 Omeros Announces It Has Unlocked 35 Percent of Class A Orphan GPCRs
--Four Additional Orphans Unlocked by Omeros Linked to Ovarian and Prostate Cancer, Obesity and Diabetes, Suspended Animation and Schizophrenia-- SEATTLE , Feb. 23, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported that it has identified compounds that interact selectively with
02/21/12 Omeros Awarded $1 Million NIDA Grant for NMUR2 Drug Development Program
-- Potential for Non-Addictive Analgesics --   SEATTLE , February 21, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has been awarded a grant of $1.04 million from the National Institute on Drug Abuse (NIDA) to fund further drug development against neuromedin U
02/08/12 Omeros to Present at the 14th Annual BIO CEO & Investor Conference
SEATTLE , Feb. 8, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A.
02/07/12 Omeros Provides Update on Ongoing OMS302 Phase 3 Clinical Trial
SEATTLE , Feb. 7, 2012  /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that recent positive clinical developments have allowed it to revise the planned analysis for its ongoing Phase 3 clinical trial evaluating OMS302, which Omeros believes expands opportunities for the
02/01/12 BioMed Realty and Omeros Sign New 64,500 Square Foot Lease in Seattle
SAN DIEGO , Feb. 1, 2012 /PRNewswire/ --  BioMed Realty Trust, Inc. (NYSE: BMR) announced today the signing of a new 15-year lease with Omeros Corporation (NASDAQ: OMER) for BioMed's Waterfront Research Center property located in Seattle , Washington.  A clinical-stage biopharmaceutical company
01/10/12 Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
--Five Additional Orphans Unlocked by Omeros Linked to Liver Cancer, Cognitive Impairments, Cardiovascular and Inflammatory Disorders-- SEATTLE , Jan. 10, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported that it has identified compounds that interact selectively with each of
11/30/11 Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
Four Additional Orphans Unlocked by Omeros Linked to Melanoma, Anxiety, Gastrointestinal Disorders and Respiratory and Immune Disorders-- SEATTLE, Nov. 30, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today reported that with its identification of compounds that interact
11/29/11 Omeros Announces Submission to European Medicines Agency of Paediatric Investigation Plan Letter of Intent for OMS302
SEATTLE , Nov. 29, 2011 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has submitted to the European Medicines Agency (EMA) a letter of intent to file its Paediatric Investigation Plan (PIP) for OMS302, the Company's product candidate for use during intra-ocular lens
11/22/11 Omeros to Present at 23rd Annual Piper Jaffray Health Care Conference
  SEATTLE , Nov. 22, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory
11/08/11 Omeros Corporation Reports Third Quarter 2011 Financial Results
SEATTLE, Nov. 8, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its
10/11/11 Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302
Data from Initial Trial Expected in First Quarter of 2012-- SEATTLE, Oct. 11, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today announced that the first patients have been treated in the Company's Phase 3 clinical program evaluating OMS302 in intra-ocular lens replacement
09/13/11 Omeros Unlocks Four Additional Orphan GPCRs
Orphans Linked to Cancer, Metabolism, Eye, Immune and CNS Disorders-- SEATTLE, Sept. 13, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today reported that it has identified compounds that interact selectively with each of four additional orphan G protein-coupled receptors
09/06/11 Omeros to Present at Rodman and Renshaw 13th Annual Healthcare Conference
SEATTLE, Sept. 6, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that
08/09/11 Omeros Corporation Reports Second Quarter 2011 Financial Results
SEATTLE, Aug. 9, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its
08/03/11 Omeros to Present at Two Upcoming Conferences
SEATTLE, Aug. 3, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
06/29/11 Omeros Announces Publication of Phase 2 Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
SEATTLE, June 29, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today reported the publication of results from a Phase 2 trial investigating OMS103HP in patients undergoing arthroscopic partial meniscectomy surgery. OMS103HP is Omeros' product candidate being developed for use
06/27/11 Omeros Unlocks Orphan GPCRs Linked to Leukemia and Sleep Disorders
SEATTLE, June 27, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today reported that it has identified compounds that interact with orphan G protein-coupled receptors (GPCRs) P2Y8 and OPN4. P2Y8 (also known as P2RY8) is associated with acute lymphoblastic leukemia (ALL), an
06/02/11 Omeros to Present at the Jefferies 2011 Global Healthcare Conference
SEATTLE, June 2, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
05/31/11 Omeros Unlocks Orphan GPCR Family Linked to Metabolic and Psychotic Disorders
Omeros Has Now Discovered Compounds for Approximately 10% of Class A Orphans-- SEATTLE, May 31, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today reported that it has identified compounds that interact with orphan G protein-coupled receptors (GPCRs) GPR27 and GPR173.
05/24/11 Omeros Reports Allowance of Additional Patent for Arthroscopic Product
Extends Patent Protection for OMS103HP into 2020 -- SEATTLE, May 24, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today reported the allowance by the US Patent and Trademark Office (USPTO) of an additional patent claiming the composition of OMS103HP, the Company's arthroscopic
05/19/11 Omeros Announces Clinical Development Programs for OMS103HP and OMS302
Phase 3 Clinical Programs Advancing for Two PharmacoSurgery(TM) Products -- SEATTLE, May 19, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today announced that it is advancing two of its product candidates from its PharmacoSurgery(TM) platform - OMS103HP for arthroscopic
05/10/11 Omeros Corporation Reports First Quarter 2011 Financial Results
SEATTLE, May 10, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system, today announced its financial
05/05/11 Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
Promising Data for the Treatment of Nicotine Addiction -- SEATTLE, May 5, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today announced that its phosphodiesterase 7 (PDE7) inhibitors demonstrated robust efficacy in animal models of nicotine addiction.
04/27/11 Omeros to Present at Deutsche Bank Health Care Conference
SEATTLE, April 27, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
04/19/11 Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
SEATTLE, April 19, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today announced that research on mannan-binding lectin-associated serine protease-2 (MASP-2) has been published in the April 18, 2011 Early Online Edition of the Proceedings of the National Academy of Sciences
04/11/11 Omeros to Present at Future Leaders in the Biotech Industry Conference
SEATTLE, April 11, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
04/07/11 Omeros Announces Publication of Data From its PPAR-gamma Addiction Program
Publication is Honored in the Journal of Biological Psychiatry -- SEATTLE, April 7, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today announced that research on the PPAR-gamma agonists it is developing in its Addiction franchise has been published in the April 1, 2011 issue of
04/04/11 Omeros to Present at Needham Healthcare Conference
SEATTLE, April 4, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
03/31/11 Omeros Reports Outcome of Phase 3 Trials of OMS103HP
Webcast Conference Call Scheduled for 5:30pm EDT Today-- SEATTLE, March 31, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central
03/23/11 Omeros' Ophthalmology Product OMS302 Achieves Co-Primary Endpoints in Phase 2b Clinical Study
OMS302 Maintains Pupil Dilation During Cataract Surgery and Reduces Postoperative Pain -- SEATTLE, March 23, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation,
03/15/11 Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
SEATTLE, March 15, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced financial results for
03/02/11 Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
SEATTLE, March 2, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has identified compounds that interact selectively with two orphan G protein-coupled receptors (GPCRs) linked to pancreatic cancer (GPR182) and cognitive disorders (GPR12).
02/22/11 Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
Promising Data for the Treatment of Addiction and Compulsive Disorders -- SEATTLE, Feb. 22, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER) today announced that its exclusive license to phosphodiesterase 7 (PDE7) inhibitors from Daiichi Sankyo Co., Ltd.
02/10/11 Omeros Announces Publication of Data From Antifibrinolytic Program
Publication is Honored in the Journal of Biological Chemistry -- SEATTLE, Feb. 10, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER) today announced that research on the antifibrinolytic agents it is developing has been published in the February 11, 2011 issue of the Journal of
02/01/11 Omeros Announces Eligibility of OMS103HP for EMA Centralized Marketing Application
SEATTLE, Feb. 1, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER) today announced that the European Medicines Agency (EMA) has confirmed that OMS103HP is eligible to be submitted for marketing approval in the European Union (EU) through the EMA centralized procedure.
01/05/11 Omeros Licenses Novel Antifibrinolytic Agents
IND-Enabling Activities Already Initiated -- SEATTLE, Jan. 5, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license from The Regents of the University of California to a new series of antifibrinolytic agents.
12/29/10 Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
SEATTLE, Dec. 29, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced results from the Phase 1/2 clinical
11/24/10 Omeros to Present at Piper Jaffray Health Care Conference
SEATTLE, Nov. 24, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A.
11/23/10 Omeros Announces Completion of Acquisition of Assay for GPCR Program
SEATTLE, Nov. 23, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it has completed the
11/17/10 Omeros Names Dr. Kenneth Ferguson as Vice President, Development
SEATTLE, Nov. 17, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced the appointment of Kenneth M.
11/09/10 Omeros Identifies Orphan GPCR-Targeting Compound Potentiating Chemotherapeutic Activity
SEATTLE, Nov. 9, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that a compound identified by the
11/04/10 Omeros Corporation Reports Third Quarter 2010 Financial Results
SEATTLE, Nov. 4, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced its financial results for the third
11/03/10 Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
SEATTLE, Nov. 3, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it has been awarded non-taxable
10/25/10 Omeros Receives $20 Million from Vulcan Capital and $5 Million Grant Award from Washington State's Life Sciences Discovery Fund to Advance its GPCR Program
Company to Host Webcast Conference Call Today at 4 p.m. EDT SEATTLE, Oct 25, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous
10/22/10 Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
SEATTLE, Oct 22, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that the Company will host a webcast
10/15/10 Omeros to Present at the BioCentury NewsMakers Conference
SEATTLE, Oct 15, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A.
10/14/10 Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
SEATTLE, Oct 14, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER) today announced that the National Institute on Drug Abuse (NIDA) has provided an additional grant to fund clinical studies for the Company's Addiction program. This grant, which is for a total of approximately $3.6
09/08/10 Omeros to Present at the Rodman & Renshaw Global Investment Conference
SEATTLE, Sept 08, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A.
08/10/10 Omeros Reports Second Quarter 2010 Financial Results
SEATTLE, Aug 10, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced financial results for the three and
08/05/10 Omeros to Webcast Presentation at Canaccord Genuity 30th Annual Growth Conference
Company to Issue Second Quarter Financial Results After Market on August 10th SEATTLE, Aug 05, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of
07/29/10 Omeros Secures $40 Million Committed Equity Financing Facility
SEATTLE, July 29, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has secured a committed equity financing facility under which it may sell up to $40 million of its shares of common stock to Azimuth Opportunity, Ltd.
07/27/10 Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
SEATTLE, July 27, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it has enrolled
06/29/10 Omeros Successfully Unlocks Orphan GPCRs
Opportunity for Development of Unprecedented Number of Novel Drug Targets - SEATTLE, June 29, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has successfully identified compounds that interact with three orphan G protein-coupled receptors
06/03/10 Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
SEATTLE, June 3, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A.
05/13/10 Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
SEATTLE, May 13, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company, today announced that, based on successful preclinical studies, the Company has selected a clinical candidate for its MASP-2 antibody program and has initiated
05/12/10 Omeros Reports First Quarter 2010 Financial Results
SEATTLE, May 12, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced financial results for
05/03/10 Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
SEATTLE, May 3, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced additional data from a Phase 2 trial of OMS103HP, its PharmacoSurgery(TM) product candidate for arthroscopy, showing that patients treated with OMS103HP during arthroscopic meniscectomy
04/29/10 Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
SEATTLE, April 29, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A.
03/31/10 Omeros Corporation Reports Fourth Quarter and Year-End 2009 Financial Results
Company Also Announces Two Additions to Management Team- SEATTLE, March 31, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the
03/31/10 Omeros Reports Phase 2 Data Showing Multiple Clinical Benefits in Patients Undergoing Arthroscopic Meniscectomy Surgery
Webcast Conference Call to be Held Today at 4:30pm ET - SEATTLE, March 31, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced that a Phase 2 clinical trial of OMS103HP, its PharmacoSurgery(TM) product candidate for arthroscopy, demonstrated that patients
03/15/10 Omeros Corporation to Host Conference Call on Fourth Quarter and Full Year 2009 Results on March 31
SEATTLE, March 15 /PRNewswire-FirstCall/ --Omeros Corporation (Nasdaq:OMER - News), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it will hold a conference call
03/09/10 Omeros Licenses PDE7 Compounds for Parkinson's Disease Program
SEATTLE, March 9, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license to compounds from Asubio Pharma Co., Ltd. for use in its PDE7 program, which is focused on the treatment of movement disorders.
01/28/10 Omeros Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program
SEATTLE, Jan 28, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced that the National Institute on Drug Abuse (NIDA) is providing support for the Company's Addiction program. NIDA will fund substantially all of the costs of a Phase 2 clinical study to be
12/09/09 Daniel K. Spiegelman Elected to Board of Directors of Omeros
SEATTLE, Dec 09, 2009 /PRNewswire via COMTEX News Network/ -- Omeros Corporation today announced that its Board of Directors has elected Daniel K. Spiegelman to serve on the Company's Board. Mr. Spiegelman has also been appointed to serve as Chairman of the Audit Committee.
11/19/09 Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
SEATTLE, Nov 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced unaudited financial results for the third quarter ended September 30, 2009. For the three months ended September 30, 2009, Omeros reported a net loss of $3.9 million, or $1.34
11/13/09 Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
SEATTLE, WA, Nov 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it
10/07/09 Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
SEATTLE, Wash., Oct 07, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Omeros Corporation today announced the pricing of its initial public offering of 6.82 million shares of its common stock at a price of $10.00 per share. The underwriters have the option to purchase up to an additional
08/11/09 Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
Seattle, WA - August 11, 2009 - Omeros Corporation today announced results from the Phase 1/Phase 2 clinical trial of OMS302, the Company's ophthalmologic PharmacoSurgery™ product candidate. OMS302 is a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation
08/05/09 Omeros Appoints New Vice President of Clinical Development
Seattle, WA - August 5, 2009 - Omeros Corporation today announced the appointment of Stephen R. Murray, M.D., Ph.D. as Vice President of Clinical Development. Dr. Murray will oversee clinical trial strategies and protocols at Omeros, and currently is leading the ongoing clinical studies for Omeros'
01/28/09 Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
Seattle, WA - January 28, 2009 - Omeros Corporation today announced that it was awarded $3.1 million in a second tranche of equity and grant funding from The Stanley Medical Research Institute (SMRI) to support late-stage preclinical development of the Company's proprietary product candidates for
01/06/09 Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target
Seattle, Washington - January 6, 2009 - Omeros Corporation today announced that The Michael J. Fox Foundation has awarded it a $465,000 grant against milestones to support the Company's collaboration with The Parkinson's Institute evaluating Omeros' recent discovery of a new target for the
12/09/08 Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
Seattle, WA - December 9, 2008 - Omeros Corporation today announced favorable results from a Phase 1 vehicle-controlled study of OMS201, another of Omeros' PharmacoSurgery™ product candidates, for use during urological surgery. The Phase 1 study of OMS201 enrolled patients undergoing endoscopic
09/24/08 Omeros and BlueCrest Announce $20 Million Debt Facility
Seattle, WA and Chicago, IL, September 24, 2008 - Omeros Corporation, a Seattle-based biopharmaceutical company, today announced the establishment of a $20 million debt facility with BlueCrest Capital Finance. The facility consists of a $5 million term loan drawn by Omeros at closing and the right,
09/17/08 Omeros and The Parkinson's Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
Seattle, Washington and Sunnyvale, California - September 17, 2008 - Omeros Corporation and The Parkinson's Institute and Clinical Center today announced that they have entered into a collaboration to evaluate a novel target, proprietary to Omeros, for the treatment of movement disorders.
09/09/08 Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
Third PharmacoSurgery™ Platform Product Candidate in Clinical Trials Seattle, Washington - September 9, 2008 - Omeros Corporation today announced that it is enrolling patients in a Phase1/Phase 2 study of OMS302, the Company's third PharmacoSurgery™ product candidate, for use during ophthalmologic
08/26/08 Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
Seattle, WA - August 26, 2008 - Omeros Corporation today announced the publication of the results from a Phase 1/Phase 2 trial investigating OMS103HP in arthroscopic anterior cruciate ligament (ACL) reconstruction surgery. OMS103HP is an investigational drug product that is added to arthroscopic
08/19/08 Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
Seattle, USA and Oslo, Norway- August 19, 2008 - Omeros Corporation, a Seattle-based clinical-stage biopharmaceutical company, and Affitech AS, a Norwegian human antibody therapeutics company, today announced that they have entered into an agreement for the discovery and development of fully human
05/20/08 Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
Seattle, Washington - May 20, 2008 - Omeros Corporation today announced that it has begun patient enrollment for the Phase 1 study of OMS201, the Company's second PharmacoSurgeryTM drug product candidate, for use during urological surgery. At least 24 patients undergoing unilateral ureteroscopic
02/12/07 Omeros Raises More Than $63 Million in Financing
Seattle, WA - February 12, 2007 - Omeros today announced that it has raised in excess of $63 million in an oversubscribed Series E equity financing. New investors, including Aravis Ventures, ARCH Venture Partners, subsidiaries of American Financial Group, Grosvenor Funds, Novartis Venture Fund,
01/09/07 Omeros receives up to $9 million toward development of schizophrenia treatment
Seattle, WA -- January 9, 2007 - Omeros Corporation announced today that the Stanley Medical Research Institute (SMRI) will provide up to $9 million in equity and grant funding toward the development of Omeros' proprietary drug candidate for the treatment of schizophrenia.
09/07/06 Omeros Acquires Nura
-Acquisition adds world-renowned scientists and expands pipeline- Seattle, WA - September 7, 2006 - Omeros Corporation, a Seattle-based biopharmaceutical company, announced today that it has acquired Nura, Inc., a company developing treatments for pain and other central nervous system disorders